FindTrial
Sign In

GL-ONC1

BIOLOGICAL6 trials

Sponsors

Genelux GmbH, Genelux Corporation, Memorial Sloan Kettering Cancer Center, Andrew Lowy

Conditions

Acute Myeloid Leukemia (6 Patients)Advanced Cancers (Solid Tumors)Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)Cancer of Head and NeckLung CancerPeritoneal CarcinomatosisSolid Organ Cancers

Phase 1

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
CompletedNCT00794131
Genelux GmbHAdvanced Cancers (Solid Tumors)
Start: 2008-11-30End: 2015-11-30Updated: 2025-04-24
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
CompletedNCT01443260
Genelux GmbHPeritoneal Carcinomatosis
Start: 2012-02-29End: 2014-09-30Updated: 2025-04-30
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
CompletedNCT01584284
Genelux CorporationCancer of Head and Neck
Start: 2012-04-30End: 2015-07-31Updated: 2015-08-25
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
CompletedNCT01766739
Memorial Sloan Kettering Cancer CenterLung Cancer
Start: 2013-01-31End: 2024-10-24Updated: 2024-10-26
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
TerminatedNCT02714374
Andrew LowySolid Organ Cancers
Start: 2016-03-25End: 2019-08-06Updated: 2024-08-06

Unknown Phase

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
NCT03420430
Genelux CorporationAcute Myeloid Leukemia (6 Patients), Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)
Updated: 2024-09-25

Related Papers

Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma
Frontiers in Immunology2023-02-1621 citations
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Clinical Cancer Research2018-05-17107 citations
Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion.
Journal of Clinical Oncology2015-05-2014 citations
Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma.
Journal of Clinical Oncology2015-05-203 citations
Results of the first study on intraperitoneal virotherapy employing a recombinant vaccinia virus genetically engineered to selectively replicate in and destroy cancer cells
Zeitschrift für Gastroenterologie2014-08-11
Virotherapy of peritoneal carcinomatosis
Zeitschrift für Gastroenterologie2013-08-16
Overcoming oncolysis resistance by double infections with vaccine-derived state-of-the-art virotherapeutics
Zeitschrift für Gastroenterologie2013-08-16